The global BPH treatment market is expected to grow from USD 33,031.10 million in 2024 to USD 47,045.80 million by 2034, at a ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

A team from the Institute of Cancer Research, London, found NXP800 slowed the growth of prostate cancer cells, including ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

Over the coming months, it is anticipated Pluvicto will be available for eligible patients at most of Ontario’s Cancer ...

A Dundalk-area man is the first person in Canada to receive a new, publicly funded treatment that better targets prostate cancer cells and is shown to prolong life.

The FDA has approved Gemtesa® for men with overactive bladder symptoms receiving pharmacological therapy for BPH.

Drug treatment of BPH was initially viewed with suspicion by urologists, but has gradually achieved widespread acceptance, with excellent consequences for patients. Urologists had further ...

In the coming months, health ministry anticipates PLUVICTO will be available for eligible patients at most of Ontario’s ...

The Maple Grove-based company plans to use the money to fund a clinical trial and to hire more employees. Here's what might ...